Purpose: This randomized controlled experimental study verified the educational effect of a mobile-based parental education program for preventing unintentional early childhood injuries. Methods: (Design and Methods) From August 2019 to September 2019, 167 participants were recruited from parenting portal sites and randomly assigned to an e-learning group (n = 59), an electronic document distribution (EDD) group (n = 53), and a control group with no intervention (n = 55). Participants self-reported data regarding their safety knowledge and behavior before and after the experiment. Each intervention group received an e-learning program and electronic educational documents for two weeks and a satisfaction survey. Using an ADDIE (Analysis, Design, Development, Implementation, and Evaluation) model, the relevant e-learning contents were developed with the Storyline 360 program. The collected data were analyzed using 1-way ANOVA, 2-way ANOVA, and independent t-test. Results: were as follows: (1) Postintervetion, no significant differences regarding safety knowledge were observed between the e-learning group, EDD group, and control group. (2) Postintervention, statistically significant differences regarding safety behaviors were observed between the three groups: 3.52 ± 0.28 (e-learning group), 3.51 ± 0.28 (EDD group), and 3.32 ± 0.25 (control group) (F = 10.091, p < .001). (3) No significant differences regarding education-related satisfaction were observed. Conclusions The mobile-based educational program for preventing unintentional injuries positively affected safety behavior in this study. Mobile-based parental education programs could contribute toward effectively preventing unintentional injuries in early childhood because many parents can use these without time and space constraints.

Purpose: This study explored the validity of a new type of thermometer and parent satisfaction with the new device. This 24-hour continuous monitoring smart wearable wireless thermometer (TempTraq®) uses a very small semiconductor sensor with a thin patch-like shape. Methods: We obtained 397 sets of TempTraq® axillary temperatures and tympanic temperatures from 44 pediatric patients. Agreement between the axillary and tympanic measurements, as well as the validity of the TempTraq® axillary temperatures, were evaluated. Satisfaction surveys were completed by 41 caregivers after the measurements. Results: The TempTraq® axillary temperatures demonstrated a strong positive correlation with the tympanic temperatures. The Bland-Altman plot and analysis of TempTraq® axillary temperatures and tympanic temperatures showed that the mean difference was +0.45 ℃, the 95% limits of agreement were -0.57 to +1.46 ℃. Based on a tympanic temperature of 38 ℃, the results of validity of fever detection were sensitivity 0.85 and specificity 0.86. Satisfaction scores for TempTraq® temperature measurement were all > 4 points (satisfactory). Conclusion TempTraq® smart axillary temperature measurement is an appropriate method for measuring children's temperatures since it was highly correlated to tympanic temperatures, had a reliable level of sensitivity and specificity, and could be used safely and conveniently.

Objectives: This study aimed to assess the effectiveness of relapse prevention interventions involving behavioral and pharmacological treatment among abstinent smokers. Methods: This rapid review was conducted using MEDLINE, Cochrane CENTRAL, CINAHL, Embase, KMbase, and KoreaMed to identify studies published until June 20, 2020. The participants were abstinent smokers who quit smoking on their own, due to pregnancy, hospitalization, or by participating in a smoking cessation program. We found a systematic review that fit the objective of this study and included 81 randomized controlled trials (RCTs). Studies that did not present information on smoking cessation status, had no control group, or used reward-based interventions were excluded. Random effect and fixed effect meta-analyses were used to estimate the relative risk (RR) and 95% confidence interval (CI). In subgroup analyses, differences between subgroups were verified based on the participant setting, characteristics, intervention type, and intensity. Results Following screening, 44 RCTs were included in the meta-analysis. The review reported no differences in the success rate of relapse prevention between the behavioral interventions. Pharmacotherapy interventions showed higher success rates (RR, 1.15; 95% CI, 1.05−1.26; I2=40.71%), depending on prior abstinence duration and the drug type. Conclusions: The results indicated that pharmacotherapy has a significant effect on preventing relapse among abstinent smokers.

Objectives: This study aimed to assess the effectiveness of relapse prevention interventions involving behavioral and pharmacological treatment among abstinent smokers. Methods: This rapid review was conducted using MEDLINE, Cochrane CENTRAL, CINAHL, Embase, KMbase, and KoreaMed to identify studies published until June 20, 2020. The participants were abstinent smokers who quit smoking on their own, due to pregnancy, hospitalization, or by participating in a smoking cessation program. We found a systematic review that fit the objective of this study and included 81 randomized controlled trials (RCTs). Studies that did not present information on smoking cessation status, had no control group, or used reward-based interventions were excluded. Random effect and fixed effect meta-analyses were used to estimate the relative risk (RR) and 95% confidence interval (CI). In subgroup analyses, differences between subgroups were verified based on the participant setting, characteristics, intervention type, and intensity. Results Following screening, 44 RCTs were included in the meta-analysis. The review reported no differences in the success rate of relapse prevention between the behavioral interventions. Pharmacotherapy interventions showed higher success rates (RR, 1.15; 95% CI, 1.05−1.26; I2=40.71%), depending on prior abstinence duration and the drug type. Conclusions: The results indicated that pharmacotherapy has a significant effect on preventing relapse among abstinent smokers.